研究发现:每天喝一杯牛奶的女性患乳腺癌的风险可以提高50%
Study Finds Breast Cancer Risk Can Rise by 50% for Women Who Drink a Cup of Milk Every Day

Study Finds Breast Cancer Risk Can Rise by 50% for Women Who Drink a Cup of Milk Every Day

研究发现:每天喝一杯牛奶的女性患乳腺癌的风险可以提高50%

本月在《国际流行病学杂志》上发表的一项新研究发现,每天喝牛奶的女性患乳腺癌的风险可能较高。这项观察性研究追踪了北美地区52795名女性,历时7.9年,该研究的作者加里·弗雷泽(Gary Fraser)博士说,主要发现之一是“每天喝一杯酒,相关风险降低了。高达50%,对于每天喝两到三杯的人,患病的风险进一步增加到70%至80%。”研究人员发现,大豆制品与罹患乳腺癌的风险无关。

到研究结束时,已有1,057名女性被诊断出患有乳腺癌,约占研究女性总数的2%。目前,大约有13%的风险是美国女性一生中会罹患乳腺癌。

美国癌症协会(ACS)估计,到2020年,将有42,170名妇女死于乳腺癌。这是仅次于肺癌的女性死于癌症的第二大原因,ACS估计,今年将有63,220名美国妇女死于此。

乳腺癌患者可能很快就会有另一个选择

生物技术公司Seattle Genetics(NASDAQ:SGEN)正在努力将一种新的乳腺癌药物图卡替尼推向市场。该药物可治疗HER2阳性乳腺癌,这是一种侵袭性癌症,可以迅速生长和分裂。大约五分之一的乳腺癌属于这一分类。西雅图遗传学公司去年年底申请了新药申请,美国食品药品监督管理局本月初宣布已授予该药优先审查权。

A new study released this month in the International Journal of Epidemiology has found that women who drink milk every day may be at an elevated risk of developing breast cancer. The observational study followed 52,795 women in North America over a period of 7.9 years, and one of the key findings, according to the study's author, Dr. Gary Fraser, was that "by drinking up to one cup per day, the associated risk went up to 50 percent, and for those drinking two to three cups per day, the risk increased further to 70 percent to 80 percent."Researchers found that soy products, however, weren't associated with a higher risk of breast cancer.

By the end of the study, there were 1,057 women diagnosed with breast cancer, or about 2% of the total women in the study. Currently, there's about a 13% risk that an American woman will develop breast cancer at some point during her life.

The American Cancer Society (ACS) estimates that 42,170 women will die from breast cancer in 2020. It's the second leading cause of cancer death in women behind lung cancer, to which the ACS estimates 63,220 American women will succumb this year.

Breast cancer patients may soon have another option

Biotech company Seattle Genetics (NASDAQ:SGEN) is working on bringing a new breast cancer drug to market, tucatinib. The drug treats HER2-positive breast cancer, an aggressive form of cancer that can grow and divide rapidly. Approximately one in five breast cancers fall into this classification. Seattle Genetics applied for a new drug application late last year, and the Food and Drug Administration announced earlier this month that it has granted the drug a priority review.

A new study released this month in the International Journal of Epidemiology has found that women who drink milk every day may be at an elevated risk of developing breast cancer. The observational study followed 52,795 women in North America over a period of 7.9 years, and one of the key findings, according to the study's author, Dr. Gary Fraser, was that "by drinking up to one cup per day, the associated risk went up to 50 percent, and for those drinking two to three cups per day, the risk increased further to 70 percent to 80 percent."Researchers found that soy products, however, weren't associated with a higher risk of breast cancer.

本月在《国际流行病学杂志》上发表的一项新研究发现,每天喝牛奶的女性患乳腺癌的风险可能较高。这项观察性研究追踪了北美地区52795名女性,历时7.9年,该研究的作者加里·弗雷泽(Gary Fraser)博士说,主要发现之一是“每天喝一杯酒,相关风险降低了。高达50%,对于每天喝两到三杯的人,患病的风险进一步增加到70%至80%。”研究人员发现,大豆制品与罹患乳腺癌的风险无关。

By the end of the study, there were 1,057 women diagnosed with breast cancer, or about 2% of the total women in the study. Currently, there's about a 13% risk that an American woman will develop breast cancer at some point during her life.

到研究结束时,已有1,057名女性被诊断出患有乳腺癌,约占研究女性总数的2%。目前,大约有13%的风险是美国女性一生中会罹患乳腺癌。

The American Cancer Society (ACS) estimates that 42,170 women will die from breast cancer in 2020. It's the second leading cause of cancer death in women behind lung cancer, to which the ACS estimates 63,220 American women will succumb this year.

美国癌症协会(ACS)估计,到2020年,将有42,170名妇女死于乳腺癌。这是仅次于肺癌的女性死于癌症的第二大原因,ACS估计,今年将有63,220名美国妇女死于此。

Breast cancer patients may soon have another option

乳腺癌患者可能很快就会有另一个选择

Biotech company Seattle Genetics (NASDAQ:SGEN) is working on bringing a new breast cancer drug to market, tucatinib. The drug treats HER2-positive breast cancer, an aggressive form of cancer that can grow and divide rapidly. Approximately one in five breast cancers fall into this classification. Seattle Genetics applied for a new drug application late last year, and the Food and Drug Administration announced earlier this month that it has granted the drug a priority review.

生物技术公司Seattle Genetics(NASDAQ:SGEN)正在努力将一种新的乳腺癌药物图卡替尼推向市场。该药物可治疗HER2阳性乳腺癌,这是一种侵袭性癌症,可以迅速生长和分裂。大约五分之一的乳腺癌属于这一分类。西雅图遗传学公司去年年底申请了新药申请,美国食品药品监督管理局本月初宣布已授予该药优先审查权。